Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165495 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2B | |
| SCHEMBL7346085 | 0.88 | ITGB3 (0.79) | ITGB3ITGA2B | |
| SCHEMBL7346090 | 0.85 | ITGB3 (0.77) | ITGB3ITGA2B | |
| SCHEMBL7346663 | 0.85 | ITGB3 (0.77) | ITGB3ITGA2B | |
| Xemilofiban SCHEMBL50663 | 0.85 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Xemilofiban SCHEMBL5163315 | 0.85 | ITGB3 (1.00) | ITGB3ITGA2B | |
| SCHEMBL7544623 | 0.84 | ITGB3 (0.79) | ITGB3ITGA2B | |
| Xemilofiban SCHEMBL609244 | 0.84 | ITGB3 (0.98) | ITGB3ITGA2B | |
| SCHEMBL7345475 | 0.84 | ITGB3 (0.80) | ITGB3ITGA2B | |
| SCHEMBL7376276 | 0.83 | ITGB3 (1.00) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020177172-A1 | RESTORATION OF PLATELET AGGREGATION BY ANTIBODY ADMINISTRATION AFTER GPIIB/IIIA ANTAGONIST TREATMENT | WESTERN MICHIGAN UNIVERSITY | 2002-11-28 | — | — | US | claimed |
| EP-0912901-B1 | METHOD AND REAGENT FOR MONITORING BLOOD LEVELS OF ANTIPLATELET COMPOUNDS | SEARLE & CO (US) | 2001-11-07 | — | — | EP | claimed |
| EP-0542708-B1 | Substituted beta-amino acid derivatives useful as platelet aggregation inhibitors | MONSANTO CO (US) | 2001-05-30 | — | — | EP | claimed |
| US-6150114-A | Method and reagent for monitoring blood levels of antiplantelet compounds | G. D. SEARLE & CO. (US) | 2000-11-21 | — | — | US | claimed |
| WO-2000029019-A1 | RESTORATION OF PLATELET AGGREGATION BY ANTIBODY ADMINISTRATION AFTER GPIIB/IIIA ANTAGONIST TREATMENT | G.D. SEARLE & CO. (US) | 2000-05-25 | — | — | WO | claimed |
| EP-0839128-B1 | PROCESS FOR THE PREPARATION OF ETHYL 3S-[[4-[[4-(AMINOIMINOMETHYL)PHENYL]AMINO]-1,4-DIOXOBUTYL]AMINO]-4-PENTYNOATE | SEARLE & CO (US) | 2000-04-05 | — | — | EP | claimed |
| EP-0912901-A1 | METHOD AND REAGENT FOR MONITORING BLOOD LEVELS OF ANTIPLATELET COMPOUNDS | G.D. SEARLE & CO. (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1997043650-A1 | METHOD AND REAGENT FOR MONITORING BLOOD LEVELS OF ANTIPLATELET COMPOUNDS | G.D. SEARLE & CO. (US) | 1997-11-20 | — | — | WO | claimed |
| EP-0614360-B1 | SUBSTITUTED BETA-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | SEARLE & CO (US) | 1997-03-19 | — | — | EP | claimed |
| EP-0614360-A1 | SUBSTITUTED -g(b)-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS. | SEARLE & CO (US) | 1994-09-14 | — | — | EP | claimed |
| US-5344957-A | Amidinoiphenyl-substituted | G.D. SEARLE & CO. (US) | 1994-09-06 | — | — | US | claimed |
| EP-0542708-A1 | Substituted B-amino acid derivatives useful as platelet aggregation inhibitors | MONSANTO COMPANY (US) | 1993-05-19 | — | — | EP | claimed |
| WO-1993007867-A1 | SUBSTITUTED β-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-04-29 | — | — | WO | claimed |
| US-20030118584-A1 | Restoration of platelet aggregation by antibody administration after GPIIB/IIIa antagonist treatment | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | disclosed |
| US-20020177172-A1 | RESTORATION OF PLATELET AGGREGATION BY ANTIBODY ADMINISTRATION AFTER GPIIB/IIIA ANTAGONIST TREATMENT | WESTERN MICHIGAN UNIVERSITY | 2002-11-28 | — | — | US | disclosed |
| EP-0912901-B1 | METHOD AND REAGENT FOR MONITORING BLOOD LEVELS OF ANTIPLATELET COMPOUNDS | SEARLE & CO (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-0614360-A1 | SUBSTITUTED -g(b)-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS. | SEARLE & CO (US) | 1994-09-14 | — | — | EP | disclosed |
| US-5344957-A | Amidinoiphenyl-substituted | G.D. SEARLE & CO. (US) | 1994-09-06 | — | — | US | disclosed |
| EP-0542708-A1 | Substituted B-amino acid derivatives useful as platelet aggregation inhibitors | MONSANTO COMPANY (US) | 1993-05-19 | — | — | EP | disclosed |
| WO-1993007867-A1 | SUBSTITUTED β-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118584-A1 | Restoration of platelet aggregation by antibody administration after GPIIB/IIIa antagonist treatment | F13B, GP6, FGB | ITGB3 12/4885ITGA2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.